natgillin/translations-raw huggingface dataset:
In CLL, Gazyvaro has been shown to significantly delay the disease getting worse in patients previously untreated who had other medical conditions and were therefore ineligible for fludarabine-based therapy.
Dokazano je da lijek Gazyvaro značajno odgađa pogoršavanje KLL-a u bolesnika koji nisu prethodno liječeni i koji su imali druga zdravstvena stanja te stoga nisu ispunjavali uvjete za terapiju koja se temelji na fludarabinu.
In CLL, the overall incidence of grade 3 or 4 cardiac disorders was low both in the first-line study (4% R-FC, 3% FC) and in the relapsed/refractory study (4% R-FC, 4% FC).
Kod KLL-a je ukupna incidencija srčanih poremećaja stupnja 3 ili 4 bila niska i u ispitivanju prve linije liječenja (4% R-FC, 3% FC) i u ispitivanju relapsirajuće/refraktorne bolesti (4% R-FC, 4% FC).
In CLL, the overall incidence of grade 3 or 4 nervous system disorders was low both in the first-line study (4% R-FC, 4% FC) and in the relapsed/refractory study (3% R-FC, FC).
Kod KLL-a je ukupna incidencija poremećaja živčanog sustava stupnja 3 ili 4 bila niska i u ispitivanju prve linije liječenja (4% R-FC, 4% FC) i u ispitivanju relapsirajuće/refraktorne bolesti (3% R-FC, 3% FC).
In CLL, Zydelig is used in combination with another medicine (rituximab or ofatumumab) in patients who have received at least one previous treatment and in patients who have genetic mutations in their cancer cells called 17p deletion or TP53 mutation who cannot be treated with any other therapy.
U slučaju CLL-a, Zydelig se koristi u kombinaciji s drugim lijekom (rituksimabom ili ofatumumabom) u bolesnika koji su primili najmanje jednu prethodnu terapiju i u bolesnika koji imaju genetske mutacije u svojim stanicama raka naziva delecije 17p ili mutacije TP53 koji se ne mogu liječiti nijednom drugom terapijom .
In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses ≥ 750 mg (phase I study).
Kod KML-a, citopenije su, osobito neutropenija i trombocitopenija, bile stalan nalaz u svim ispitivanjima, s naznakom da je incidencija veća uz visoke doze ≥750 mg (ispitivanje faze I).
In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses ≥ 750 mg (phase I study).
Kod KML-a, citopenije su, osobito neutropenija i trombocitopenija, bile stalan nalaz u svim ispitivanjima, s naznakom da je incidencija veća uz visoke doze 750 mg (ispitivanje faze I).
In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses ≥ 750 mg (phase I study).
Kod KML-a, citopenije su, osobito neutropenija i trombocitopenija, bile stalan nalaz u svim ispitivanjima, s naznakom da je učestalost veća uz visoke doze 750 mg (ispitivanje faze I).
In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses ≥ 750 mg (phase I study).
U KML-u, citopenije su, osobito neutropenija i trombocitopenija, bile stalan nalaz u svim ispitivanjima, s naznakom da je incidencija veća uz visoke doze 750 mg (ispitivanje faze I).
In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses  750 mg (phase I study).
Kod KML-a, citopenije su, osobito neutropenija i trombocitopenija, bile stalan nalaz u svim ispitivanjima, s naznakom da je incidencija veća uz visoke doze 750 mg (ispitivanje faze I).
In Cohort A of this study, trametinib did not demonstrate clinical activity in patients who had progressed on a prior BRAF inhibitor therapy.
U kohorti A ovoga ispitivanja, trametinib nije pokazao kliničku aktivnost u bolesnika u kojih je nastupila progresija tijekom prethodne terapije BRAF inhibitorom.
In colon cancer, Xeloda on its own has been compared with the combination of 5-FU and folinic acid (a medicine that enhances the effects of 5-FU) in 1,987 patients who had previously had surgery for their cancer.
U slučaju karcinoma kolona, lijek Xeloda kao monoterapija uspoređen je s kombinacijom 5-FU-a i folne kiseline (lijeka koji pojačava djelovanje 5-FU) u 1.987 bolesnika koji su prethodno podvrgnuti kirurškom zahvatu radi odstranjenja karcinoma.
In colon cancer, Xeloda was also as effective as 5-FU and folinic acid, with about two-thirds of the patients remaining disease-free throughout the 3.8 years of the study.
U slučaju karcinoma kolona, lijek Xeloda je također bio jednako djelotvoran kao 5-FU i folna kiselina, pri čemu se u otprilike dvije trećine bolesnika bolest nije vratila tijekom 3,8 godina ispitivanja.
in combinatin with efavirenz
indinavira/ritonavira u dozi od 800/100 BID)
In combination studies of emtricitabine with protease inhibitors, nucleoside, nucleotide and non-nucleoside analogue inhibitors of HIV reverse transcriptase, additive to synergistic effects were observed.
Pri ispitivanjima emtricitabina u kombinaciji s inhibitorima proteaze, nukleozidnim, nukleotidnim i nenukleozidnim analozima inhibitora reverzne transkriptaze HIV-a, opaženi su aditivni do sinergistički učinci.
In combination treatment, the recommended starting dose of capecitabine should be reduced to 800 - 1000 mg/m2 when administered twice daily for 14 days followed by a 7-day rest period, or to 625 mg/m2 twice daily when administered continuously (see section 5.1).
U kombiniranoj terapiji preporučenu početnu dozu kapecitabina potrebno je smanjiti na 800 – 1000 mg/m² i uzimati dvaput dnevno tijekom 14 dana, nakon čega slijedi 7 dana pauze ili na 625 mg/m² dvaput dnevno pri kontinuiranoj (svakodnevnoj) primjeni (vidjeti dio 5.1).
In combination treatment, the recommended starting dose of capecitabine should be reduced to 800 – 1000 mg/m2 when administered twice daily for 14 days followed by a 7-day rest period, or to 625 mg/m2 twice daily when administered continuously (see section 5.1).
U kombiniranoj terapiji preporučenu početnu dozu kapecitabina potrebno je smanjiti na 800 – 1000 mg/m² i uzimati dvaput dnevno tijekom 14 dana, nakon čega slijedi 7 dana pauze ili na 625 mg/m² dvaput dnevno pri kontinuiranoj (svakodnevnoj) primjeni (vidjeti dio 5.1).
in combination with a statin (other cholesterol-lowering medicines), or a statin plus other fat- lowering medicines, in patients who do not adequately respond to the maximum dose of the statin;
u kombinaciji sa statinom (drugim lijekovima za snižavanje kolesterola) ili statinom i drugim lijekovima za smanjivanje koncentracije masti, u bolesnika koji ne odgovaraju primjereno na maksimalnu dozu statina; kao monoterapiju ili u kombinaciji s drugim lijekovima za snižavanje masti u bolesnika koji ne podnose ili ne mogu primati statine.
in combination with a statin (other cholesterol-lowering medicines), or a statin plus other fat- lowering medicines, in patients who do not adequately respond to the maximum tolerated dose of the statin; alone or in combination with other fat-lowering medicines in patients who cannot tolerate or cannot be given statins.
u kombinaciji sa statinom (drugim lijekom za snižavanje kolesterola) ili statinom i drugim lijekovima za snižavanje masnoća u krvi, u bolesnika koji ne odgovaraju primjereno na maksimalnu podnošljivu dozu statina; kao monoterapija ili u kombinaciji s drugim lijekovima za snižavanje masnoća u krvi u bolesnika koji ne podnose ili ne mogu primati statine.
in combination with a sulphonylurea (another type of diabetes medicine) in patients who are not satisfactorily controlled with a sulphonylurea used on its own and in whom metformin is not suitable; in combination with both metformin, and a sulphonylurea or a PPAR-gamma agonist, in patients who are not satisfactorily controlled on the two medicines; in combination with insulin, with or without metformin, in patients who are not satisfactorily controlled on a stable dose of insulin.
u kombinaciji sa sulfonilurejom (drugom vrstom lijeka za dijabetes) u bolesnika koji nisu u zadovoljavajućoj mjeri kontrolirani sulfonilurejom korištenim kao monoterapija i u kojih primjena metformina nije primjerena; u kombinaciji s metforminom i sulfonilurejom ili agonistom PPAR-gama, u bolesnika koji se ne mogu u zadovoljavajućoj mjeri kontrolirati s ova dva lijeka; u kombinaciji s inzulinom, s ili bez metformina, u bolesnika koji se ne mogu u zadovoljavajućoj mjeri kontrolirati stabilnom dozom inzulina.
in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
u kombinaciji sa sulfonilurejom i metforminom, kada se prehranom i fizičkom aktivnošću uz dvojnu terapiju ovim lijekovima ne postiže odgovarajuća kontrola glikemije. u kombinaciji s inzulinom, s ili bez metformina, kada se ovim režimom uz prehranu i fizičku aktivnost ne postiže odgovarajuća kontrola glikemije.
In combination with acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting, also known as aspirin), there is an increased risk of major haemorrhages (bleeding) (see section “Other medicines and Xagrid”).
U kombinaciji s acetilsalicilnom kiselinom (tvar prisutna u mnogim lijekovima koja se primjenjuje za ublažavanje bolova i snižavanje temperature, a također i za sprječavanje zgrušavanja krvi, poznata i kao aspirin), postoji povećani rizik za obilne hemoragije (krvarenja) (pogledajte dio "Drugi lijekovi i Xagrid").
in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.
u kombinaciji s adjuvantnom kemoterapijom koja uključuje docetaksel i karboplatin.
in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy.
u kombinaciji s inhibitorom aromataze za žene u postmenopauzi s metastatskom bolesti uz pozitivne hormonske receptore, a koje trenutno nisu kandidati za kemoterapiju.
in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.
u kombinaciji s inhibitorom aromataze u liječenju postmenopauzalnih bolesnica s metastatskim rakom dojke pozitivnim na hormonske receptore, koje nisu prethodno liječene trastuzumabom.
In combination with anaesthesia and tumour resection further side effects may occur:
U kombinaciji s anestezijom i resekcijom tumora mogu se pojaviti sljedeće nuspojave:
In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
U kombinaciji s bortezomibom za liječenje progresivnog multiplog mijeloma u bolesnika koji su prethodno primili najmanje jednu liniju liječenja i koji su prošli presađivanje koštane srži ili za isto nisu bili pogodni.
in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).
u kombinaciji s kapecitabinom za bolesnike s uznapredovalom ili metastatskom bolesti koja je progredirala nakon prethodnog liječenja koje je moralo uključivati antracikline i taksane te nakon liječenja metastatske bolesti trastuzumabom (vidjeti dio 5.1).
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m2 every three weeks, combined with capecitabine at 1250 mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period.
U kombinaciji s kapecitabinom, preporučena doza docetaksela je 75 mg/m2 svaka tri tjedna u kombinaciji s kapecitabinom u dozi od 1250 mg/m2 dvaput dnevno (unutar pola sata nakon obroka) u trajanju od 2 tjedna, nakon čega slijedi tjedan dana pauze.
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m² every three weeks, combined with capecitabine at 1250 mg/m² twice daily (within 30 minutes after a meal) for 2 weeks followed by 1-week rest period.
U kombinaciji s kapecitabinom, preporučena doza docetaksela je 75 mg/m2 svaka tri tjedna u kombinaciji s kapecitabinom u dozi od 1250 mg/m2 dvaput dnevno (unutar pola sata nakon obroka) u trajanju od 2 tjedna, nakon čega slijedi tjedan dana pauze.
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m² every three weeks, combined with capecitabine at 1250 mg/m² twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period.
U kombinaciji s kapecitabinom, preporučena doza docetaksela je 75 mg/m2 svaka tri tjedna u kombinaciji s kapecitabinom u dozi od 1250 mg/m2 dvaput dnevno (unutar pola sata nakon obroka) u trajanju od 2 tjedna, nakon čega slijedi tjedan dana pauze.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST > 1.5 × ULN
Iz pivotalnog kliničkog ispitivanja kombinacije s cisplatinom i 5-fluorouracilom za liječenje bolesnika s adenokarcinomom želuca, isključeni su bolesnici s ALT i/ili AST više od 1,5 puta većim od GGN te alkalnom fosfatazom više od 2,5 puta većom od GGN i bilirubinom više od 1 puta većim od GGN.
in combination with dexamethasone (an anti-inflammatory medicine), in adults whose disease has been treated at least once in the past; for the treatment of adults with previously untreated (newly diagnosed) multiple myeloma, who are not eligible for bone marrow transplant.
u kombinaciji s deksametazonom (protuupalnim lijekom), u odraslih bolesnika čija je bolest bar jedanput prethodno liječena; za liječenje odraslih bolesnika s prethodno neliječenim (novodijagnosticiranim) multiplim mijelomom koji ne ispunjavaju kriterije za transplantaciju koštane srži.
in combination with diabetes medicines taken by mouth in combination with a type of diabetes medicines called GLP-1 receptor agonists that are given by injection.
u kombinaciji s lijekovima protiv dijabetesa koji se uzimaju peroralno u kombinaciji s tipom lijekova protiv dijabetesa naziva agonist GLP-1 koji se primjenjuju injekcijom.
in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
u kombinaciji s docetakselom (vidjeti dio 5.1) indiciran u liječenju bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha citotoksične kemoterapije.
in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
u kombinaciji s docetakselom (vidjeti dio 5.1) za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha citotoksične kemoterapije.
in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
u kombinaciji s docetakselom u liječenju bolesnika koji nisu prethodno primali kemoterapiju za metastatsku bolest.
In combination with docetaxel: an increased incidence of grade 3 or 4 treatment-related adverse reactions and treatment-related serious adverse reactions were observed in patients 60 years of age or more (see section 5.1).
U kombinaciji s docetakselom: u bolesnika u dobi od 60 ili više godina primijećena je povećana incidencija nuspojava 3. ili 4. stupnja i ozbiljnih nuspojava povezanih s liječenjem (vidjeti dio 5.1).
in combination with efavirenz
indinavira/ritonavira u dozi od 800/100 BID)
In combination with fluoropyrimidines, the frequency of cardiac ischaemia including myocardial infarction and congestive heart failure as well as the frequency of hand-foot syndrome (palmar-plantar erythrodysaesthesia) were increased compared to that with fluoropyrimidines.
U kombinaciji s fluoropirimidinima, u odnosu na samostalnu primjenu fluoropirimidina, povećala se učestalost ishemije srca, uključujući infarkt miokarda, kongestivno zatajenje srca kao i učestalost sindroma šake i stopala (palmarno-plantarne eritrodisestezije).
in combination with injections of a short- or rapid-acting insulin at mealtimes
u kombinaciji s injekcijama kratko ili brzo djelujućeg inzulina u vrijeme obroka
in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
u kombinaciji s inzulinom (tj. trojna kombinirana terapija), kao dodatak dijeti i tjelovježbi, za poboljšanje kontrole glikemije u bolesnika u kojih nije postignuta odgovarajuća kontrola inzulinom u stabilnoj dozi i metforminom.
in combination with irinotecan-based chemotherapy, in first-line in combination with FOLFOX, as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
u kombinaciji s kemoterapijom na bazi irinotekana, u prvoj liniji liječenja u kombinaciji s FOLFOX-om, kao samostalan lijek nakon neuspjeha terapije na bazi oksaliplatina i irinotekana i kod bolesnika koji ne podnose irinotekan.
In combination with its subtype selective receptor-binding characteristics, with high selectivity and low affinity for the benzodiazepine type I receptor, these properties are responsible for the overall characteristics of Sonata.
U kombinaciji sa svojim karakteristikama selektivnog vezanja za benzodiazepinski podtip receptora i uz visoku selektivnost i nizak afinitet za benzodiazepinski receptor tipa I, ova su svojstva odgovorna za cjelokupne karakteristike Sonate.
In combination with Kyprolis, lenalidomide is administered as 25 mg orally on days 1–21 and dexamethasone is administered as 40 mg orally or intravenously on days 1, 8, 15, and 22 of the 28 day cycles.
U kombinaciji s lijekom Kyprolis, lenalidomid se primjenjuje peroralno u dozi od 25 mg od 1. – 21. dana, a deksametazon se primjenjuje peroralno ili intravenski u dozi od 40 mg, 1., 8., 15. i 22. dana ciklusa od 28 dana.
in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.
u kombinaciji s metforminom (tj. trojna kombinirana terapija), kao dodatak dijeti i tjelovježbi, za poboljšanje kontrole glikemije u bolesnika (posebice onih s prekomjernom tjelesnom težinom) u kojih nije postignuta odgovarajuća kontrola maksimalnom podnošljivom dozom metformina i pioglitazona.
In combination with metformin in drug-naïve patients
U kombinaciji s metforminom u prethodno neliječenih bolesnika
in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
u kombinaciji s metforminom u bolesnika koji ne mogu postići zadovoljavajuću kontrolu samo metforminom ili sa sulfonilurejom (drugom vrstom lijeka protiv dijabetesa) kada primjena metformina nije primjerena u bolesnika koji ne mogu postići zadovoljavajuću kontrolu samo sulfonilurejom;
in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
u kombinaciji s metforminom u bolesnika u kojih se ne može postići zadovoljavajuća kontrola samo metforminom, ili sulfonilurejom (drugom vrstom lijeka protiv dijabetesa) ako metformin nije prikladan u bolesnika koji se ne mogu zadovoljavajuće kontrolirati samo sulfonilurejom;
in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
u kombinaciji s metforminom, kada se prehranom i fizičkom aktivnošću uz monoterapiju metforminom ne postiže odgovarajuća kontrola glikemije.
in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated
u kombinaciji s metotreksatom ili kao jedinu terapiju u bolesnika koji ne podnose metotreksat ili je kod njih metotreksat kontraindiciran.
in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.
u kombinaciji s metotreksatom ili kao jedinu terapiju u bolesnika koji ne podnose metotreksat ili im je metotreksat kontraindiciran.
in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.
u kombinaciji s metotreksatom ili kao jedinu terapiju u bolesnika koji ne podnose metotreksat ili je kod njih metotreksat kontraindiciran.
in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter (see sections 4.4 and 5.1).
u kombinaciji s neoadjuvantnom kemoterapijom nakon koje slijedi adjuvantna terapija lijekom Herceptin za lokalno uznapredovalu (uključujući upalnu) bolest ili tumore promjera > 2 cm (vidjeti dijelove 4.4 i 5.1).
In combination with oral glucose­lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4 and 5.1 for available data on the different combinations).
U kombinaciji s oralnim lijekovima za snižavanje razine glukoze i/ili bazalnim inzulinom kada oni, u kombinaciji s dijetom i tjelovježbom, ne osiguravaju odgovarajuću regulaciju glikemije (vidjeti dijelove 4.4 i 5.1 za dostupne podatke za različite kombinacije).
in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 for available data on different combinations) in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.
u kombinaciji s drugim lijekovima za snižavanje razine glukoze, uključujući inzulin, u bolesnika u kojih glikemija nije dovoljno dobro regulirana metforminom i tim lijekovima (vidjeti dijelove 4.4, 4.5 i 5.1 za dostupne podatke o različitim kombinacijama) u bolesnika koji se već liječe kombinacijom dapagliflozina i metformina u zasebnim tabletama.
In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).
U kombinaciji s drugim lijekovima uobičajena doza za odrasle može biti manje od 1250 mg/m2 tjelesne površine i moguće je da ćete uzimati tablete u različitom vremenskom razdoblju (npr. svaki dan, bez prekida).
In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).
U kombinaciji s drugim lijekovima uobičajena doza za odrasle može biti manje od 1250 mg/m2 tjelesne površine, i moguće je da ćete uzimati tablete u različitom vremenskom razdoblju (npr. svaki dan, bez prekida).
in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.
u kombinaciji s paklitakselom u liječenju bolesnika koji prethodno nisu primali kemoterapiju za metastatsku bolest i onih koji nisu pogodni za liječenje antraciklinom.